NervGen Pharma to Present at the 63rd International Spinal Cord Society Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - September 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., NervGen's Chief Medical Officer, will present at the 63rd International Spinal Cord Society (ISCoS) Annual Scientific Meeting, taking place on September 22-25, 2024, in Antwerp, Belgium. The ISCoS Annual...
2024-09-16 8:30 AM EDT
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, on Tuesday, September 10, 2024, at 9:30 a.m. EDT. Members of management will be available for one-on-one investor...
2024-08-27 8:30 AM EDT
NervGen Pharma Reports Q2 2024 Financial Results and Operational Updates
Vancouver, British Columbia--(Newsfile Corp. - August 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial and operational results for the second quarter ended June 30, 2024. "During the quarter we implemented a communica
2024-08-22 8:30 AM EDT
NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
Vancouver, British Columbia--(Newsfile Corp. - August 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting at the Canaccord Genuity 44th Annual Growth Conference, on August 13, 2024, at 10:00 a.m. EDT and members of management will be available for one-on-one investor meetings at the...
2024-08-06 8:30 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - August 2, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 30,000 incentive stock options to employees of the company and 15,000 incentive stock options to existing consultants providing investor relations services exercisable at a price of $2.98 per share. The employee options...
2024-08-02 4:14 PM EDT
NervGen Pharma Appoints Neil Klompas to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - July 22, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced the appointment of Mr. Neil Klompas to the company's Board of Directors. "We are very pleased that Neil is joining our Board at a pivotal time, as we prepare for future growth," said
2024-07-22 8:30 AM EDT
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced its plans for the development of a new drug candidate, NVG-300, with a focus on three initial indications: ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury (SCI). NVG-300 is a new biologic molecule discovered at...
2024-06-25 8:30 AM EDT
NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
Vancouver, British Columbia--(Newsfile Corp. - June 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Mr. Mike Kelly, President & CEO, will be presenting a corporate update at the 2nd Annual Spinal Cord Injury Investor Symposium ("2nd SCIIS"), presented by Lineage Cell Therapeutics, Inc., California Institute for Regenerative Medicine and...
2024-06-20 8:30 AM EDT
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the company has granted 950,000 incentive stock options to directors and consultants of the company exercisable at a price of $1.79 per share (the "Options"). 400,000 of the Options are exercisable for a period of five years and vest equally every...
2024-06-06 6:00 PM EDT
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
Vancouver, British Columbia--(Newsfile Corp. - June 5, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announces the results of its Annual General Meeting of Shareholders ("AGM") held on June 4, 2024. "We appreciate the support demonstrated by our shareholders at this AGM," said Mike Kelly, NervGen's President & CEO. "We are also pleased that
2024-06-05 8:30 AM EDT
NervGen Pharma to Present Two Posters at the American Spinal Injury Association 51st Annual Scientific Meeting
Vancouver, British Columbia--(Newsfile Corp. - May 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced today that Daniel Mikol, MD, Ph.D., Chief Medical Officer, will be presenting two posters at the upcoming American Spinal Injury Association (ASIA) 51st Annual Scientific Meeting being held on May 20-23, 2024, in San Juan, Puerto Rico. ASIA gathers...
2024-05-17 8:30 AM EDT
NervGen Pharma Reports Q1 2024 Financial Results and Operational Updates
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial and operational results for the first quarter ended March 31, 2024. "Recruitment in our Phase 1b/2a clinical study of NVG-291 for in
2024-05-16 8:30 AM EDT
NervGen Files Management Information Circular and Announces Board of Directors Transition
Vancouver, British Columbia--(Newsfile Corp. - May 7, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that its Management Information Circular, in connection with its upcoming 2024 Annual General Meeting of Shareholders to be held on June 4, 2024 (the "Meeting"), is being delivered to shareholders and is available on the...
2024-05-07 8:30 AM EDT
NervGen Engages Russo Partners LLC to Provide Public Relations Services
Vancouver, British Columbia--(Newsfile Corp. - April 25, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that it has engaged Russo Partners LLC ("Russo Partners"), a New York based full-service strategic communications firm to provide media and public relations and related services for the Company. Russo Partners was engaged...
2024-04-25 8:30 AM EDT
NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) a clinical-stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the year ended December 31, 2023. "Recruitment in our Phase 1b/2a clini
2024-04-17 9:00 AM EDT
NervGen Completes $23 Million Bought Deal Financing
Vancouver, British Columbia--(Newsfile Corp. - March 28, 2024) - NervGen Pharma Corp. (TSXV: NGEN) ("NervGen" or the "Company") is pleased to announce the closing of its previously announced public offering (the "Offering") including the full exercise of the underwriters' over-allotment option for aggregate gross proceeds to the Company of C$23,011,788. The Offering was made pursuant to an underwriting agreement entered into with a syndicate of underwriters led by Stifel Canada and including...
2024-03-28 9:01 AM EDT
NervGen Pharma Recognized as a Top 50 TSX Venture Exchange Company
Vancouver, British Columbia--(Newsfile Corp. - February 21, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has been recognized by the TSX Venture Exchange as a 2023 Top 50 Company. The 2024 TSX Venture 50™ showcases the strongest performances on the TSX Venture Exchange over the last year. Comprising the top 10 companies from each of five industry sectors, the...
2024-02-21 8:00 AM EST
NervGen Pharma Grants Stock Options
Vancouver, British Columbia--(Newsfile Corp. - February 20, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it has granted incentive stock options to the Company's employees, including 505,200 to the Company's Officers exercisable at a price of $3.48 per share for a period of 10 years and that vest equally every six months over a two-year...
2024-02-20 5:37 PM EST
NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury
Vancouver, British Columbia--(Newsfile Corp. - February 15, 2024) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today announced that it is on track to complete enrollment in Q2 2024 and deliver the data readout in Q3 2024 of the chronic cohort in the Company's Phase 1b/2a proof-of-concept, double blind, randomized placebo-controlled clinical trial for its
2024-02-15 8:47 AM EST
NervGen Pharma Reports Q3 2023 Financial Results and Operational Updates
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended September 30, 2023.
2023-11-09 8:30 AM EST